Social networks
1,424Activities
Technologies
Entity types
Location
5349 AE Oss, Netherlands
Oss
Netherlands
Employees
Scale: 11-50
Estimated: 25
Engaged corporates
0Added in Motherbase
3 years, 6 months agoTranslating NET biology into novel therapies for inflammatory diseases
Citryll has translated a deep understanding of the neutrophil extracellular trap (NET) pathway to therapeutically address its central role in a broad range of inflammatory diseases. With a unique dual mode of action, the company’s lead antibody, CIT-013, has reached the clinic by demonstrating a precise and powerful ability to control NETs and NETosis. Citryll is initially developing CIT-013 as a novel drug for rheumatoid arthritis and hidradenitis suppurativa, which may serve as enabling indications for a wide spectrum of inflammatory diseases. The initial clinical trials with CIT-013 are expected to provide the foundation for a new treatment paradigm.
Immunology, Therapeutics development, Neutrophil Extracellular Traps, Inflammatory diseases, Antibody development, Rheumatoid Arthritis, and Hidradenitis Suppurativa